What's Happening?
Flatiron Health announced it will present seven research abstracts at the ISPOR Europe 2026 conference, focusing on advancing global oncology evidence for health technology assessment (HTA). The research examines how real-world evidence can support HTA,
the transportability of oncology findings across countries, and the validation of AI-derived data. Key studies include evaluating the applicability of evidence across different healthcare systems, such as a comparison of patient characteristics and first-line treatment patterns in metastatic non-small cell lung cancer (NSCLC) cohorts from the U.S. and Finland. Another analysis explores how second-line treatment patterns influence estimates of first-line treatment effects on real-world overall survival in advanced NSCLC. Additionally, research extends Flatiron’s VALID framework to assess the quality of AI-extracted data in UK prostate cancer and examines cross-country differences in laboratory monitoring for liver toxicity in breast cancer patients.
Why It's Important?
The ability to effectively use real-world evidence and AI-derived data is crucial for making informed decisions about cancer treatment access and reimbursement globally. Health technology assessment bodies and researchers need to understand if evidence from one healthcare system is applicable to another, considering variations in patient populations, treatment practices, and monitoring standards. Flatiron Health's research addresses these complexities, aiming to strengthen the evidence base that informs access to cancer treatments. This work is vital for ensuring that innovative therapies reach patients efficiently and equitably, impacting public health policy and healthcare economics in the U.S. and internationally.
What's Next?
Flatiron Health will host a speaking session at ISPOR Europe on scaling AI-curated oncology data across countries, discussing data accuracy, consistency, and clinical relevance. The presented research will contribute to ongoing discussions about harmonizing HTA processes and leveraging diverse data sources for oncology research. The insights gained from these studies could lead to improved methodologies for evaluating cancer treatments, potentially influencing regulatory frameworks and reimbursement decisions. Flatiron Health will continue to develop its AI-powered oncology intelligence platform, Flatiron Telescope, to provide deeper insights from its global Panoramic datasets.
Beyond the Headlines
This research highlights the growing intersection of artificial intelligence, real-world data, and health economics in oncology. The challenge of 'transportability' of evidence across different healthcare systems is a fundamental issue in global health, and Flatiron's structured approach to addressing it could set new standards. The validation of AI-derived data is particularly critical, as AI tools become more prevalent in healthcare, ensuring that these insights are reliable and clinically sound. This work not only aims to improve access to cancer treatments but also to foster a more data-driven and evidence-based approach to healthcare policy, potentially leading to more efficient and equitable healthcare systems worldwide.
